TY - JOUR
T1 - Myeloid immune-checkpoint inhibition enters the clinical stage
AU - van den Berg, Timo K.
AU - Valerius, Thomas
PY - 2019/5/1
Y1 - 2019/5/1
N2 - The first-in-human study of anti-CD47 antibodies blocking CD47–SIRPα interactions in combination with rituximab in patients with non-Hodgkin lymphoma shows encouraging clinical responses accompanied with mild levels of toxicity. Inhibition of the CD47–SIRPα interaction might provide a generic method of promoting the effects of antitumour antibodies in a variety of cancer types. This reveals, for the first time, an innate immune checkpoint as a bona fide target for therapy.
AB - The first-in-human study of anti-CD47 antibodies blocking CD47–SIRPα interactions in combination with rituximab in patients with non-Hodgkin lymphoma shows encouraging clinical responses accompanied with mild levels of toxicity. Inhibition of the CD47–SIRPα interaction might provide a generic method of promoting the effects of antitumour antibodies in a variety of cancer types. This reveals, for the first time, an innate immune checkpoint as a bona fide target for therapy.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85058965272&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30573788
U2 - https://doi.org/10.1038/s41571-018-0155-3
DO - https://doi.org/10.1038/s41571-018-0155-3
M3 - Comment/Letter to the editor
C2 - 30573788
SN - 1759-4774
VL - 16
SP - 275
EP - 276
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 5
ER -